Corbus Pharmaceuticals Operating Income Over Time
| CRBP Stock | USD 7.63 0.21 2.83% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Corbus Pharmaceuticals Performance and Corbus Pharmaceuticals Correlation. Can Biotechnology industry sustain growth momentum? Does Corbus have expansion opportunities? Factors like these will boost the valuation of Corbus Pharmaceuticals. Projected growth potential of Corbus fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Corbus Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Corbus Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Corbus's balance sheet. Smart investors calculate Corbus Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Corbus Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Corbus Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Corbus Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Corbus Pharmaceuticals and related stocks such as Applied Therapeutics, Elicio Therapeutics, and Molecular Partners Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APLT | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (13.5 M) | (45.6 M) | (94.5 M) | (105.6 M) | (83 M) | (64.5 M) | (104.3 M) | (93.9 M) | (98.6 M) |
| ELTX | (419.2 K) | (419.2 K) | (419.2 K) | (397.8 K) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (38.6 M) | (55.3 M) | (39.3 M) | (23.7 M) | (35.7 M) | (45 M) | (40.5 M) | (42.5 M) |
| MOLN | 7.1 M | 7.1 M | 7.1 M | 7.1 M | 1.8 M | (2.2 M) | (19.5 M) | (25.8 M) | (37.4 M) | (36.7 M) | (58.3 M) | (63.4 M) | 116.6 M | (61.1 M) | (61.2 M) | (55.1 M) | (52.3 M) |
| CRDF | (5.4 M) | (3 M) | (4.8 M) | (10.7 M) | (14.9 M) | (25.3 M) | (40.1 M) | (25.6 M) | (17.1 M) | (16.7 M) | (19.1 M) | (28.9 M) | (39.9 M) | (45.4 M) | (48.7 M) | (43.8 M) | (41.6 M) |
| RANI | (27.1 M) | (27.1 M) | (27.1 M) | (27.1 M) | (27.1 M) | (27.1 M) | (27.1 M) | (27.1 M) | (27.1 M) | (27.1 M) | (16.5 M) | (51.6 M) | (63.5 M) | (66.1 M) | (53.3 M) | (48 M) | (50.4 M) |
| MIST | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (23.8 M) | (57.9 M) | (50.7 M) | (43.1 M) | (59.6 M) | (61.1 M) | (42.1 M) | (37.9 M) | (39.8 M) |
| FBRX | (23 M) | (23 M) | (23 M) | (23 M) | (23 M) | (23 M) | (31.7 M) | (37.6 M) | (45.9 M) | (4.1 M) | (14.2 M) | (21.5 M) | (13.9 M) | (32.5 M) | (36.6 M) | (42.1 M) | (44.2 M) |
| PEPG | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.9 M) | (27.1 M) | (68.3 M) | (84.8 M) | (97.7 M) | (88 M) | (83.6 M) |
| IPHA | (6.4 M) | (7.6 M) | (3.4 M) | (2.8 M) | (20 M) | (10.8 M) | 7.6 M | (40 M) | 5.1 M | (27.1 M) | 1.1 M | (47.8 M) | (57.4 M) | (12.7 M) | (51.6 M) | (46.4 M) | (44.1 M) |
| ALEC | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (32.7 M) | (57.3 M) | (114.4 M) | (195.2 M) | (37.4 M) | (137.8 M) | (151.7 M) | (145 M) | (130.5 M) | (137 M) |
Corbus Pharmaceuticals and related stocks such as Applied Therapeutics, Elicio Therapeutics, and Molecular Partners Operating Income description
Operating Income is the amount of profit realized from Corbus Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Corbus Pharmaceuticals Holding is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Corbus Pharmaceuticals Holding | CRBP |
| Classification | Cannabis |
| Business Address | 500 River Ridge |
| Exchange | NASDAQ Exchange |
USD 7.63
Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.